Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.46 |
| ▸ | CNR1 | P21554 | 11/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451251 | 0.90 | CNR2 (0.50) | CNR2CNR1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL5453757 | 0.88 | NR4A2 (0.54) | CNR2CNR1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL5456434 | 0.86 | CNR2 (0.51) | CNR2CNR1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL5448762 | 0.86 | SMN1; SMN2 (0.56) | CNR2CNR1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL5454223 | 0.84 | CNR2 (0.48) | CNR2CNR1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL5445041 | 0.84 | CNR2 (0.48) | CNR2CNR1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL14412214 | 0.84 | DRD3 (0.50) | CNR2CNR1SMN1; SMN2ALDH1A1ADRA1D | |
| SCHEMBL5451043 | 0.82 | HTR1A (0.51) | CNR2ADRA1D | |
| Hydrochloric Acid SCHEMBL5454205 | 0.81 | ADRA1D (0.55) | CNR2ADRA1D | |
| SCHEMBL5448948 | 0.81 | CNR2 (0.47) | CNR2CNR1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885CNR1 65/4885SMN1; SMN2 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.